Subsidies Granted


The immune inhibitory receptor VISTA as regulator of stemness in acute myeloid leukemia

University of Bern

Department of BioMedical Research (MEM) E808

Murtenstrasse 35

3008 Bern

Prof. PhD Carsten Riether

CHF 200’00.00


Targeting dysregulated inflammasome activation in Myeloid Malignancies

Universitätsklinik für Hämatologie Inselspital/Universitätsspital

Department for BioMedical Research, University of Bern

Murtenstrasse 40,

3000 Bern

PD. Dr. Ramanjaneyulu Allam

CHF 197'463.00


Genome-Wide CRISPR-Knockout Screen for Identification of Immunomodulatory Genes in Glioblastoma

Department of Neurology, University Hospital Zurich

Frauenklinikstrasse 26,

8091 Zürich

Prof. Dr. med. Michael Weller

CHF 175’000.00


Studying neutrophils as mediators of synthetic lethality, sensitizing breast cancer to immunotherapy

IOR Institute of Oncology Research

Via Francesco Chiesa 5

6500 Bellinzona

Prof. PhD Arianna Calcinotto

CHF 250’000.00


Role of LCMT1 in T Cell Exhaustion and Cancer Immunotherapy

Department for Biomedicine ZLF

Universitätsspital Basel

Hebelstrasse 20

4031 Basel

Dr. med. Dominic Schmid, MD-PhD student in Experimental Biomedicine | 09/2019 - present

CHF 245’380.00



Loss of cell-cycle checkpoints in order to maximize low-dose radiation-induced inflammatory responses and sensitize ovarian cancer to immune checkpoint blockade therapy

Chemin de la Fauvette 61, 1012 Lausanne

MD, PhD Fernanda Herrera 

CHF 190'000.00


Precision Oncology Targeting of Folic Acid Metabolism in Pediatric Osteosarcoma

University Children's Hospital Zürich, Steinwiesstrasse 75, 8032 Zürich

Dr. med. Univ. et Dr. phil Raphael Johannes Jonathan Morscher

CHF 241’738.00


Mitochondrial reprogramming to restore age-driven dysfunction in T cell and boost

CAR-T cell therapy

Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Biopole 3 Chemin des Boveresses 155, 1066 Epalinges

PhD Nicola Vannini Group Leader

CHF 135’808.00


Characterization and optimization of small molecules able to restore PTEN physiological levels and/or activity in prostate cancer

Head Computational Structural Biology, Institute for Research in Biomedicine, Via

Vincenzo Vela 6, 6500 Bellinzona

Dr. Andrea Cavalli, PhD

CHF 160'600.00


TAXIS — Tailored Axillary Surgery

Brustchirurgie, Universitätsspital Basel, Spitalstrasse 21, 4031 Basel

Prof. Dr. Walter Weber

CHF 126'870.00


Transcriptional regulation of T cell lymphoma development

Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona

PhD Silvia Monticelli

CHF 153'000.00


Advancing cancer immunotherapy with non-viral engineering of multifunctional CAR T cells

Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Ramistrasse 100, 8091 Zurich

PhD Assisant Professor Chiara Francesca Magnani

CHF 210'000.00


Mechanisms of cancer resistance to CAR-T cell therapy

Istituto di Ricerca in Biomedicina, Via Vincenzo Vela 6, 6500 Bellinzona

Prof. Dr. Roger Geiger

CHF 190'000.00


Use of lymphoma ex-vivo biopsies as a platform to anticipate individual response to therapies

Swiss Institute for Experimental Cancer Research EPFL, 1015 Lausanne

PhD, Associate Professor Elisa Oricchio

CHF 177’000.00


Differential role of IL-33 in colorectal cancer development

Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern

PD (Dr. Sc. Nat. ETHZ), Prof. Philippe Krebs

CHF 170’000.00


MET as a target for combined modality treatment of glioblastoma

Chairman University Hospital Zurich, Department of Neurology

Frauenklinikstrasse 26,

8091 Zurich (Switzerland)

Prof. Dr. Michael Weller

CHF 250'000.00


Impact of the tyrosine kinase inihibitor disatinib on lymphoid tissue microenvironment and tumor cell niche

Dept. OMI, University of Fribourg

Ch. du Musee 5,

1700 Fribourg (Switzerland)

Prof. Jens V. Stein

CHF 187'289.00


Identifying the mode of action of the anti-tumor immune response induced by selected Clostridiales bacteria in colorectal cancer patients

Leiter Forschung, Leiter Translationales Mikrobiom Forschungszentrum

Universitatsspital Zurich, Klinik fur Gastroenterologie and Hepatologie

Ramistrasse 100,

8091 Zurich (Switzerland)

Prof. Dr. med. Michael Scharl

CHF 168'291.00


PREDICT — Peptide Radiotracers Enabling high-contrast PD-1 targeted Diagnostic Imaging of antigen-experienced T-cells for improved prediction of response to Immune Checkpoint targeted Therapies

Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Molecular Imaging, CHUV, Department of Oncology, UNIL, Centre Hospitalier Universitaire Vaudois (CHUV)

Agora, B25A/03/094

Rue du Bugnon 25A,

1011 Lausanne (Switzerland)

Prof. Dr. Margret Schottelius

CHF 216'000.00


Immunotherapy of breast carcinoma through combination of PLGA-microsphere based vaccination with immune checkpoint blockade

Biotechnology Institute Thurgau Unterseestrasse 47

8280 Kreuzlingen (Switzerland)

Prof.Dr. Marcus Groettrup

CHF 140'000.00


“Helping the Killers”: innovative cancer immunotherapy harnessing “quasi-universal” tumor-specific CD4 T cells

Targeting of Cytokine secreting lymphocyte (TCSL) group

Department of Oncology UNIL-CHUV and Ludwig Institute for Cancer Research Biopole III, Chemin des Boveresses 155

1066 Epalinges (Switzerland)

MD, Ph.D. Camilla Jandus-Marone SNSF Assistant Professor,

CHF 150’000.00


Analysis of the tumor immune signature and effect of immunotherapy in a mouse model of small cell lung cancer.

Ecole Polytechnique Federale de Lausanne, Station 19, 1015 Lausanne (Switzerland)

Etienne Meylan, PhD

CHF 70'000.00

Extracellular ATP as target in tumor environment to improve adaptive immunity.

Institute for Research in Biomedicine (IRB), Via Vela 6, 6500 Bellinzona (Switzerland)

Fabio Grassi, MD, PhD

CHF 162'000.00

Examination of the tumor environment to boost immunotherapy in pancreatic cancer.

Experimental Pathology, University of Bern, 3000 Bern (Switzerland)

Mirjam Schenk, PhD

CHF 143'000.00

Targeting chemoresistance and tumor microenvironment in colon cancer.

Division of Experimental Pathology, CHUV 1015 Lausanne (Switzerland)

Tatiana Petrova, PhD

CHF 87'000.00

A proof-of-concept, prospective, observational study to investigate the value of Liquid Biopsies to predict tumor response after neoadjuvant chemo-radiotherapy in patients with locally advanced Rectal Cancer: the LiBReCa study.

Institute of Pathology, 6600 Locarno (Switzerland)

Prof. Dr. med. Dimitri Christoforidis

CHF 158’000.00

The ethical communication of medical diagnosis and prognosis: a certificate of advanced studies (CAS) through Medical Humanities.

Fondazione Sasso Corbaro, 6500 Bellinzona (Switzerland)

Prof. Dr. med. Roberto Malacrida

CHF 10’000.00


Uncovering the T cell-intrinsic role of NLRC5 in antitumoral responses.

Department of Biochemistry, University of Lausanne, Chemin des Boveresses 155, 1066 Epalinges (Switzerland)

Greta Guarda, PhD,

CHF 153’140.00


TCR activation is compromised in CD8 T cells transduced with a Chimeric Antigen Receptor (CAR). Implications for CAR-T cell mediated immunotherapy.

Departement of Fundamental Oncology and Ludwig Center for Cancer

Research- Biopole 3, Ch.des Boveresses 155, 1066 Epalinges


Alena Donda PhD

CHF 65’000.00


Intravital study of the traffcking of B lymphoma cells in the lymphatic compartment.

IRB, Institute for Research in Biomedicine, Via Vela 6, 6500 Bellinzona (Switzerland)

Fernandez Gonzales Santiago PhD, PhD.

CHF 200’000.00


Understanding and targeting chemoresistance in colorectal cancer.

University of Lausanne and CHUV, Ch. Des Boveresses 155, 1066 Epalinges (Switzerland)

Tatiana Petrova PhD.

CHF 70’000.00


Modulation of colorectal cancer immune contexture by gut microbiota.

Universitätsspital Basel, Zentrum für Lehre und Forschung (ZLF),

Hebelstrasse 20, 4031 Basel (Switzerland)

Giandomenica Iezzi, PD Dr. med.

CHF 120'000.00


Dissecting the association of the human palatine tonsil microbiome and HPV-driven oropharyngeal squamous cell carcinoma

Institut für Immunbiologie 

Rorschacher Strasse 95, Kantonspital St.Gallen (Switzerland)

Prof. Dr. Ludewig Burkhard

CHF 144’000.00


Novel Active Combinations Containing Bromodomain (BRD) and Extra-terminal (BET) Inhibitors for Patients with Germinal Center B-cell Type

Diffuse large B-cell lymphoma

Institute of Oncology Research, Via Vela 6, 6500 Bellinzona (Switzerland)

Eugenio Gaudio PhD

CHF 160’000.00


Role of BCL2 genetic heteroclonality in the pathogenesis of B-cell lymphomas with BCL2 rearrangement

Istituto Cantonale di Patologia, Via in Selva 24, 6600 Locarno (Switzerland)

Prof. Dr. Med. Luca Mazzucchelli

CHF 170’000.00


Oncogenic aversion: A concept towards new therapeutic avenues in prostate cancer

Institute of Oncology Research, Via Vela 6, 6500 Bellinzona (Switzerland)

Prof. Dr. med. Jean-Philippe Theurillat

CHF 170’000.00


Role of Notch signaling and therapeutic potential of exosomes in

cardiomyopathy induced by doxorubicin & trastuzumab cancer treatment

Cardiocentro Ticino, Via Tesserete 48, 6900 Lugano (Switzerland)

Prof. Dr. med. Giuseppe Vassalli

CHF 120'000.00


Dissecting critical cellular and molecular mechanisms of acute erythroleukemia

University of Basel, Department of Biomedicine, ZLF, Childhood leukemia

group, Hebelstrasse 20, 4031 Basel, (Switzerland)

Prof.   Dr.  medJürg Schwaller

CHF 120'000.00


Role of IL-33/ST2 signaling in intestinal tumorigenesis

Institute of Pathology, P.O. Box 62, Murtenstrasse 31, 3010 (Switzerland)

Philippe Krebs, PhD

CHF 120’000.00 


Co-targeting angiogenesis and immunosuppression to improve cancer therapy

ISREC-EPFL SV, Batiment SV, Station 19-Room SV2527, 1015 Lausanne (Switzerland)

Dr. med . Michele De Palma

CHF 138’000.00.


Dissecting the role of autophagy in normal and malignant B cells towards a rational novel therapeutic target in malignant B cell lymphomas 

Inselspital, Universitätsklinik für Medizinische Onkologie, 3010 Bern (Switzerland)

Dr. Urban Nowak

CHF 70’000.00.


A single-arm, phase II trial evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsiv breast cancer who desire pregnancy. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer (POSITIVE)

University of Bern, Departement of Medical Oncology, Murtenstrasse 35,

3010 Bern (Switzerland)

Dr.ssa Manuela Rabaglio 

CHF 216'000.00.


Innate Lympoid Cells (ILCs). A novel effector cell in human cancer

University of Lausanne, Ludwig Center for Cancer Research, Av. Pierre Decker 4,

1005 Lausanne (Switzerland)

Dr.ssa Camilla Jandus-Marone,

CHF 169'000.00.


Inhibition of CD27 and BCR/ABL signaling in leukemia stem cells

Institute for Medical Oncology, Inselspital University Hospital 3010 Bern (Switzerland)

Prof.  Dr. med. Adrian Ochsenbein

CHF 110’670.00.


Identification of novel genetic and epigenetic determinants for oncogenic

transformation in patients with systemic mastocytosis

Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona


Silvia Monticelli, PhD

CHF 129’740.00.


Identification of novel targets in central nervous systeminfiltration in acute T lymphoblastic leukaemia

Institutefor Research in Biomedicine (IRB), 6500 Bellinzona (Switzerland)

Fabio Grassi MD PhD


The role of MYC in cancer cell invasion and metastasis

Centrepluridisciplinaire d'Oncologie, Rue du Bugnon 46, 1011 Lausanne (Switzerland)

Anita Wolfer MD PhD

CHF 150'000.00.


Mechanism of small cell lung cancer

Divisionof Experimental Oncology, CePO, CHUV and University of Lausanne, Chemin deBoveresses 155, 1066 Epalinges (Switzerland)

Tatiana Petrova PhD

CHF 120'000.00.


Exploring the role of Toll-interacting protein in colitis-associatedcolorectal cancer development 

CHUV,BH10-535, Rue du Bugnon 46, 1011 Lausanne (Switzerland)

Dr. Michel Maillard

CHF 120’000.00.


Therole of calretinin in asbestos-induced malignant mesothelioma investigated inthe NF2+/- mouse model 

Unitof Anatomy, Dept. Of Medicine, University of Fribourg, Route AlbertGockel 1 1700 Fribourg (Switzerland)

Prof.  Beat Schwaller

CHF 85’000.00.


Functional characterization of an 11q24.3 gain contributing to the pathogenesis of diffuse large B cell lymphoma by blocking B-cell maturation Istituto Oncologico di Ricerca, Via Vela 6, 6500 Bellinzona (Switzerland)

Prof.  Dr. med. Francesco Bertoni

CHF 231’000.00.


The role of chemokine synergy-inducing molecules in controlling the tumor microenvironment, cell migration and metastasis

Institute for Research in Biomedicine, Via Vela 6, 6500 Bellinzona (Switzerland)

Dr.ssa Mariagrazia Uguccioni

CHF 173’000.00.


PI3K isoforms in melanoma formation and progression.

Institute of Biochemistry & Genetics, Department of Biomedicine, Mattenstrasse 28, Basel (Switzerland).

Romina Marone, PhD

CHF 45,200.00


Functional characterization of endoplasmic reticulum-associated protein degradation regulators implicated in tumor progression.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona (Switzerland).

Maurizio Molinari, PhD

CHF 190,000.00


Analysis of proteins that interact with the CXCR4 receptor in different tissues.

CXCR4 project, request for extension.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona (Switzerland). 

Tiziana Apuzzo, PhD

CHF 40,000.00


Exploring tumor-specific genes as potential novel drug targets in colon cancer.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).

Pascale Anderle, MD

CHF 59,000.00


Translational research workshop on gastrointestinal tumors.

ESMO (European Society for Medical Oncology)  , Lugano-Viganello, (Switzerland).

CHF 50,000.00


Optimization of endocrine therapy for the individualized treatment of breast cancer identification of new parameters as part of the TEXT study by the IBCSG (International Breast Cancer Study Group).

IOSI, Istituto Oncologico della Svizzera Italiana, Lugano-Viganello,(Switzerland).

Olivia Pagani, MD

CHF 280,000.00


Identification of prognostic abnormalities in B-cell chronic lymphocytic leukaemia.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).  

Francesco Bertoni, MD

CHF 342,000.00


Kinase (PI3K) in cancer – role for lipid compartmentalization.

Institute of Biochemistry & Genetics

Department of Biomedicine, Basel (Switzerland).      

Prof. Matthias P. Wymann, PhD

CHF 40,000.00


Squamous cell anal cancer, chemoradiation, resistance predictive molecular markers, immunohistochemistry, fluorescent in situ hybridization gene mutations.

Istituto Cantonale di Patologia, Locarno (Switzerland).  

Milo Frattini, MD

CHF 110,000.00


Analysis of proteins that interact with the CXCR4 receptor in different tissues.

CXCR4 project, application for extension.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona (Switzerland).

Tiziana Apuzzo, PhD

CHF 36,776.00


British Columbia Cancer Agency, Vancouver (Canada).

Alden Moccia, MD

CHF 124,000.00


Communication platform on the cancer system developed by the Fondazione Oncologia Lago Maggiore, Locarno (Switzerland) in collaboration with the Institute of Communication and Health of the USI, University of Lugano (Switzerland).

Augusto Pedrazzini, MD

CHF 223,900.00


Cell super-competition and the discovery of novel markers and targets for detection and/or treatment of early stages of cancer.

Istituto Cantonale di Patologia, Locarno (Switzerland).

Davide Soldini, MD, PhD

CHF 29,600.00


Opening of a Microdissection Laser Unit.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).

Carlo Catapano, MD

Pascale Anderle Pedone, MD

CHF 295,000.00


2005 San Salvatore Foundation Young Investigator Award

Mifiana Urosevic, MD, Zurich (Switzerland).

CHF 30,000.00


B2-adrenergic receptor influence in dendritic cell-based cancer vaccines.

Istituto Cantonale di Patologia, Locarno (Switzerland).

Georges Jean-Marie Maestroni, MD

CHF 106,900.00


Cellular function of HsPi of HsPI 3-kinase-C2a - assessment of its role in transcription, centrosome integrity and cell cycle regulation.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona (Switzerland).

Prof. Marcus Thelen

CHF 176,958.00


Molecular and biological mechanisms of non-Hodgkin’s lymphoma - growth at extranodal sites.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona (Switzerland).

Mariagrazia Uguccioni, MD

CHF 127,420.00


Cytogenetic studies using the FISH technique.

Istituto Cantonale di Patologia, Locarno (Switzerland).

Luca Mazzucchelli, MD, PhD

CHF 108,000.00


Role of Akt/PKB and pericytes in protecting endothelial cells against tumor necrosis factor-induced apoptosis.

Multidisciplinary Centre for Oncology, Faculty of Medicine, University of Lausanne, Epalinges (Switzerland).

Curzio Rüegg, MD

CHF 137,252.00


2002 San Salvatore Foundation Young Investigator Award

Department of Experimental Hematology, Queen Mary’s Scool of Medicine and Dentistry, London, and

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).

Francesco Bertoni, MD

CHF 30,000.00


Ticino Hospice, Lugano (Switzerland).

Development and medical presence in the Sopraceneri region

CHF 102,000.00


Molecular characterization of chromosome 11q in primary extranodal diffuse large B-cell lymphomas.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).

Francesco Bertoni, MD

CHF 180,000.00


“Pilot study: Breast cancer database (Carma)”.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).

Prof. Aron Goldhirsch, MD

Olivia Pagani, MD

Rossella Graffeo, MD

Prof. Jacques Bernier, MD

CHF 130,000.00


Research in oncological Immunology at Sloan Kettering Cancer Center,

New York (USA).

Camilla Marone, MD

CHF 10,000.00


2001 San Salvatore Foundation Young Investigator Award.

Institute of Anatomy, University of Bern (Switzerland).

Valentin Djonov, MD

CHF 30,000.00


2000 San Salvatore Foundation Young Investigator Awards.

A.F. Ochsenbein, MD

Institute for Medical Oncology, Bern University Hospital (Switzerland).

CHF 20,000.00


Luca Mazzucchelli, MD, PhD

Institute for Pathology, University of Bern (Switzerland).

CHF 20,000.00


Chemokine expression and functions in Hodgkin’s disease.

Institute for Pathology, University of Bern (Switzerland).

Luca Mazzucchelli, MD, PhD

CHF 100,000.00


Analysis of the immunoglobulin heavy chain variable region in nodal marginal zone B-cell lymphoma and lymphoplasmacytoid lymphoma.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland).

Emanuele Zucca, MD

CHF 25,000.00


Neural influence on dendritic cell generation and function.

Istituto Cantonale di Patologia, Locarno (Switzerland).

Georges Jean-Marie Maestroni, MD

CHF 25,000.00


Registry of unrelated marrow donors.

Transfusion Service of Southern Switzerland, Lugano (Switzerland).

Damiano Castelli, MD

CHF 80,000.00


1999 San Salvatore Foundation Young Investigator Award.

Uwe Zangemeister-Wittke, MD

Oncology Department, University Hospital, Zurich (Switzerland).

CHF 30,000.00


Effect of iNOS Expression on PhlP (a colon carcinogen) induced apoptosis and mutagenicity

Institute of Pharmacology and Toxicology, Lausanne (Switzerland).

Phaik Morgenthaler Leong, MD

CHF 60,000.00


Evaluating extranodal stage I and II low-grade lymphomas of the PMH.

Princess Margaret Hospital,

Department of Radiation Oncology, University of Toronto (Canada).

Thomas Lippuner, MD

CHF 30,000.00


Upgrading of BRCA1 and BRCA2 analysis in Ticino.

Laboratorio Bioanalitico SA, Savosa (Switzerland).

Alberto Pedrazzini, MD

Gianbattista Soldati, MD

CHF 60,000.00


The mitogenic action of phosphoinositide 3-kinases.

Institute of Biochemistry, University of Fribourg (Switzerland).

Matthias Paul Wymann, MD

CHF 40,000.00


Ku 32 gene transfer to augment the radiosensitivity of hamster and human tumour cells.

San Giovanni Hospital, Bellinzona (Switzerland).

J. Bernier, MD, PhD

J. Bourhis, MD

Ch. Badie, MD

CHF 72,233.00


Investigation of the clinical relevance of a novel subunit of the 26S proteasome which confers resistance to antitumour drugs in vitro and is variably expressed in tumour cell lines.

Cantonal Oncological Service, Bellinzona (Switzerland).

Vito Spataro, MD

CHF 24,000.00


Pathological role of cathepsin B in osteoarthritis - splicing of mRNA.

Centre for Experimental Rheumatology,

University of Zurich (Switzerland).

Prof. Antonio Baici, MD

CHF 89,000.00


1998 San Salvatore Foundation Young Investigator Award.

Dermatology Clinic, University Hospital Zurich (Switzerland).

Reihnard Georg Dummer, MD

CHF 30,000.00


Swiss Registry of Marrow Donors, Bern (Switzerland).

CHF 50,000.00


Phage display libraries for the identification of cell-targeting peptides for growth and activation receptors.

Brigham and Women’s Hospital, Department of Pathology, Boston (USA).

Luca Mazzucchelli, MD, PhD

CHF 45,000.00


Characterization and distribution of alpha-1 adrenoceptors in human hematopoietic cells: a basis for new therapeutic strategies in oncology?            

Istituto Cantonale di Patologia, Locarno (Switzerland).

Georges Jean-Marie Maestroni, MD

CHF 100,000.00


Study of sterol-regulated proteolytic processing of sterol regulatory element binding protein (SREBP) in vivo.

Southwestern Medical Center, Department of Molecular Genetics, University of Texas, Dallas (USA).

Luca Barella, MD

CHF 25,000.00


Gastric MALT lymphoma as a model of tumour progression: evolution from Helicobacter pylori gastritis to low-grade and high-grade lymphomas.

Cantonal Oncological Service, Bellinzona (Switzerland).

Emanuele Zucca, MD

CHF 150,000.00


Swiss Registry of Marrow Donors, Bern (Switzerland).

CHF 50,000.00


Angiogenesis, tumour neovascularization. Identification of the inhibitor that halts growth in vivo.

Laboratory of Tumor Biology and Genetics, Neurosurgery Service, CHUV, Lausanne (Switzerland).

Erwin G. Van Meir, MD

CHF 82,000.00


Analysis of the lymphocyte antigen receptor in graft-versus-host disease after HLA compatible allotransplantation of bone: one stage in the characterisation of minor histocompatibility antigens.

Cantonal Hospital, Geneva (Switzerland).

Pierre Yves Dietrich, MD

CHF 136,260.00


Graduate course in radiotherapy in France.

Department of Radiotherapy, institut Gustave-Roussy, Villejuif (France).

Susanne Diener, MD

CHF 40,000.00


Interphase cytogenetic analysis by fluorescent non-radioactive in-situ hybridization (FISH method) in the diagnosis and study of centrocytic lymphoma.

San Giovanni Hospital, ”OSG” Ticino Oncological Transplant Foundation,

Bellinzona (Switzerland).

CHF 50,000.00


Graduate course in palliative care at Edmonton (Canada).

Hans Neuenschwander, MD

CHF 30,000.00


Two-year residency at New York Blood Center, New York and the

Department of Laboratory Medicine, Georgetown University Medical

Center, Washington (USA)

Beat M. Frey, MD

CHF 100,000.00


Experiments with genetically modified cells to produce various cytokines at the laboratory of Prof. J.A. Norton, MD, St. Louis (USA)

Gene transfer program

A. Oertli, MD

CHF 40,000.00


Status of information regarding the disease and treatment, depression and anxiety in cancer patients.

University of Geneva (Switzerland).

Marc Archinard, MD   

André Haynal, MD

CHF 152,309.00


Istituto Cantonale di Patologia, Locarno (Switzerland).

Ennio Pedrinis, MD

CHF 20,286.00


ATP (adenosin triphosphate) assay. Test of the sensitivity of gynaecological and breast tumours to chemotherapeutic applications.

University Women’s Clinic, Zurich (Switzerland).

Prof. Urs Haller, MD

Ossi R. Koechli, MD

CHF 143,646.00


”Clinical Senology of Lugano” Interdisciplinary Workgroup, Lugano (Switzerland).

Marco Varini, MD

CHF 50,000.00


In vitro assay of intrinsic radioresistance as predictive test of radiocurability

San Giovanni Hospital, Bellinzona (Switzerland)

Civic Hospital, Lugano (Switzerland)

Beata Vergine Hospital, Mendrisio (Switzerland)

La Carità Hospital, Locarno (Switzerland)

Vaudois University Hospital Centre, Lausanne (Switzerland)

CHF 465,000.00


Cancer Atlas of Switzerland (Zurich/Basel).

Swiss Cancer League, Bern (Switzerland).

G. Schüler, MD

M. Bopp, MD

CHF 10,000.00


Tumor Infiltrating Lymphocytes.

Research Division, Dept. of Surgery,

University of Basel (Switzerland).

Michael Heberer, MD, PhD

CHF 260,000.00


The role of pineal gland immunity.

Istituto Cantonale di Patologia, Locarno (Switzerland).

Georges Jean-Marie Maestroni, MD

Ario Conti, MD

CHF 20,000.00


Psychological course of cancer patients.

Psychosomatic and Psychosocial Medical Unit,

University of Geneva (Switzerland).

Marc Archinard, MD

Prof. André Haynal, MD

CHF 140,000.00


Immunological recovery after chemotherapy.

La Carità Hospital, Oncology Service, Locarno (Switzerland).

Augusto Pedrazzini, MD

CHF 100,000.00


Swiss Cancer League

Kisk Committee of the Cancer League on Ionising Radiation and Cancer, Bern, (Switzerland).

CHF. 100,000.00